Estela Rodriguez: Another tumor – agnostic approval

Estela Rodriguez shared a post on X:

“Another tumor-agnostic approval.
FDA Oncology grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK positive solid tumors.”

Read further.
Source: Estela Rodriguez/X

Estela Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials. Dr. Rodriguez is known to help empower women to take charge of their own healthcare and believes in the power of mentorship.